Search

Your search keyword '"Wu,Aiping"' showing total 1,215 results
Start Over Author "Wu,Aiping"
1,215 results on '"Wu,Aiping"'

5. Ventilatory pressure parameters impact the association between acute gastrointestinal injury and all-cause mortality in mechanically ventilated patients

Author

Shao Ziqiang, Li Jiale, Sun Renhua, Wu Aiping, Ni Yin, Liu Jingquan, Guo Feng, Ying Lijun, Ge Guoping, Ding Aijun, Shi Yunchao, Liu Changwen, Xu Lei, Jiang Ronglin, Lu Jun, Lin Ronghai, Zhu Yannan, Wu Weidong, Xie Bo, and Hu Bangchuan

Subjects
Mechanical ventilation, Acute gastrointestinal injury, All-cause mortality, Plateau pressure, Driving pressure, Positive end-expiratory pressure, Medicine, Science
Abstract

Abstract Acute gastrointestinal injury (AGI) is common in mechanically ventilated (MV) patients, but the potential association between ventilatory pressure parameters and AGI grade and their impact on mortality remains unclear. This study aimed to explore the association between ventilatory pressure parameters and AGI grade, and their interaction on all-cause mortality in MV patients. This study was a secondary analysis of a multicenter, prospective, observational study that enrolled adult patients with an expected duration of mechanical ventilation ≥ 48 h from 14 general intensive care units in Zhejiang Province between March and August 2014. The AGI grade was assessed daily on the basis of gastrointestinal symptoms, intra-abdominal pressures, and feeding intolerance in the first week of admission to the ICU. This study included 331 patients (69.2% men; mean age, 64.6 ± 18.9 years). Multivariate regression analysis showed that plateau pressure (Pplat) (OR 1.044, 95% CI 1.009–1.081, P = 0.013), serum creatinine (OR 1.003, 95% CI 1.001–1.006, P = 0.042) and APACHE II score (OR 1.035, 95% CI 1.021–1.072, P = 0.045) were independently associated with global AGI grade III/IV within 7 days of ICU admission. Moreover, global AGI grade (HR 2.228, 95% CI 1.561–3.182, P

Published
2024
Full Text
View/download PDF

16. Unlocking capacities of genomics for the COVID-19 response and future pandemics

Author

Knyazev, Sergey, Chhugani, Karishma, Sarwal, Varuni, Ayyala, Ram, Singh, Harman, Karthikeyan, Smruthi, Deshpande, Dhrithi, Baykal, Pelin Icer, Comarova, Zoia, Lu, Angela, Porozov, Yuri, Vasylyeva, Tetyana I, Wertheim, Joel O, Tierney, Braden T, Chiu, Charles Y, Sun, Ren, Wu, Aiping, Abedalthagafi, Malak S, Pak, Victoria M, Nagaraj, Shivashankar H, Smith, Adam L, Skums, Pavel, Pasaniuc, Bogdan, Komissarov, Andrey, Mason, Christopher E, Bortz, Eric, Lemey, Philippe, Kondrashov, Fyodor, Beerenwinkel, Niko, Lam, Tommy Tsan-Yuk, Wu, Nicholas C, Zelikovsky, Alex, Knight, Rob, Crandall, Keith A, and Mangul, Serghei

Subjects
Biological Sciences, Bioinformatics and Computational Biology, Genetics, Human Genome, Networking and Information Technology R&D (NITRD), Vaccine Related, Infectious Diseases, Emerging Infectious Diseases, Biotechnology, Prevention, Biodefense, Generic health relevance, Infection, Good Health and Well Being, COVID-19, Genomics, Humans, Pandemics, SARS-CoV-2, Technology, Medical and Health Sciences, Developmental Biology, Biological sciences
Abstract

During the COVID-19 pandemic, genomics and bioinformatics have emerged as essential public health tools. The genomic data acquired using these methods have supported the global health response, facilitated development of testing methods, and allowed timely tracking of novel SARS-CoV-2 variants. Yet the virtually unlimited potential for rapid generation and analysis of genomic data is also coupled with unique technical, scientific, and organizational challenges. Here, we discuss the application of genomic and computational methods for the efficient data driven COVID-19 response, advantages of democratization of viral sequencing around the world, and challenges associated with viral genome data collection and processing.

Published
2022

20. Unlocking capacities of viral genomics for the COVID-19 pandemic response

Author

Knyazev, Sergey, Chhugani, Karishma, Sarwal, Varuni, Ayyala, Ram, Singh, Harman, Karthikeyan, Smruthi, Deshpande, Dhrithi, Comarova, Zoia, Lu, Angela, Porozov, Yuri, Wu, Aiping, Abedalthagafi, Malak, Nagaraj, Shivashankar, Smith, Adam, Skums, Pavel, Ladner, Jason, Lam, Tommy Tsan-Yuk, Wu, Nicholas, Zelikovsky, Alex, Knight, Rob, Crandall, Keith, and Mangul, Serghei

Subjects
Quantitative Biology - Genomics, Quantitative Biology - Populations and Evolution
Abstract

More than any other infectious disease epidemic, the COVID-19 pandemic has been characterized by the generation of large volumes of viral genomic data at an incredible pace due to recent advances in high-throughput sequencing technologies, the rapid global spread of SARS-CoV-2, and its persistent threat to public health. However, distinguishing the most epidemiologically relevant information encoded in these vast amounts of data requires substantial effort across the research and public health communities. Studies of SARS-CoV-2 genomes have been critical in tracking the spread of variants and understanding its epidemic dynamics, and may prove crucial for controlling future epidemics and alleviating significant public health burdens. Together, genomic data and bioinformatics methods enable broad-scale investigations of the spread of SARS-CoV-2 at the local, national, and global scales and allow researchers the ability to efficiently track the emergence of novel variants, reconstruct epidemic dynamics, and provide important insights into drug and vaccine development and disease control. Here, we discuss the tremendous opportunities that genomics offers to unlock the effective use of SARS-CoV-2 genomic data for efficient public health surveillance and guiding timely responses to COVID-19.

Published
2021

27. One Year of SARS-CoV-2 Evolution

Author

Wu, Aiping, Wang, Lulan, Zhou, Hang-Yu, Ji, Cheng-Yang, Xia, Shang Zhou, Cao, Yang, Meng, Jing, Ding, Xiao, Gold, Sarah, Jiang, Taijiao, and Cheng, Genhong

Subjects
Microbiology, Biological Sciences, Bioinformatics and Computational Biology, Human Genome, Prevention, Emerging Infectious Diseases, Vaccine Related, Pneumonia & Influenza, Biodefense, Lung, Infectious Diseases, Genetics, Pneumonia, Infection, Good Health and Well Being, COVID-19, Evolution, Molecular, Genome, Viral, Humans, Mutation, SARS-CoV-2, Medical Microbiology, Immunology, Biochemistry and cell biology, Medical microbiology
Abstract

Since the outbreak of SARS-CoV-2, the etiologic agent of the COVID-19 pandemic, the viral genome has acquired numerous mutations with the potential to increase transmission. One year after its emergence, we now further analyze emergent SARS-CoV-2 genome sequences in an effort to understand the evolution of this virus.

Published
2021

28. Early Introduction and Community Transmission of SARS-CoV-2 Omicron Variant, New York, New York, USA

Author

Liu, Dakai, Cheng, Yexiao, Zhou, Hangyu, Wang, Lulan, Fiel, Roberto Hurtado, Gruenstein, Yehudah, Luo, Jean Jingzi, Singh, Vishnu, Konadu, Eric, James, Keither, Lui, Calvin, Gao, Pengcheng, Urban, Carl, Prasad, Nishant, Segal- Maurer, Sorana, Wurzberger, Esther, Cheng, Genhong, Wu, Aiping, and Rodgers, William Harry

Subjects
New York, New York -- Health aspects, Epidemics -- Distribution -- Causes of -- Risk factors -- United States, Company distribution practices, Health
Abstract

During the global pandemic of SARS-CoV-2, novel variants have continuously emerged (1). Some variants constitute an increased risk to global public health and are being monitored as variants of concern [...]

Published
2023
Full Text
View/download PDF

35. Cellular, Molecular, and Immunological Characteristics of Langhans Multinucleated Giant Cells Programmed by IL-15

Author

Wang, Hongsheng, Jiang, Haiqin, Teles, Rosane MB, Chen, Yanqing, Wu, Aiping, Lu, Jing, Chen, Zhimin, Ma, Feiyang, Pellegrini, Matteo, and Modlin, Robert L

Subjects
Biomedical and Clinical Sciences, Immunology, Infectious Diseases, Genetics, Stem Cell Research, Stem Cell Research - Nonembryonic - Human, 2.1 Biological and endogenous factors, Aetiology, Inflammatory and immune system, Good Health and Well Being, Cell Communication, Cells, Cultured, Gene Regulatory Networks, Giant Cells, Langhans, Humans, Interferon-gamma, Interleukin-15, Macrophage Activation, Primary Cell Culture, RNA-Seq, Signal Transduction, T-Lymphocytes, Transcriptome, Clinical Sciences, Oncology and Carcinogenesis, Dermatology & Venereal Diseases, Clinical sciences
Abstract

Langhans multinucleated giant cells (LGCs) are a specific type of multinucleated giant cell containing a characteristic horseshoe-shaped ring of nuclei that are present within granulomas of infectious etiology. Although cytokines that trigger macrophage activation (such as IFN-γ) induce LGC formation, it is not clear whether cytokines that trigger macrophage differentiation contribute to LGC formation. Here, we found that IL-15, a cytokine that induces M1 macrophage differentiation, programs human peripheral blood adherent cells to form LGCs. Analysis of the IL-15‒treated adherent cell transcriptome identified gene networks for T cells, DNA damage and replication, and IFN-inducible genes that correlated with IL-15 treatment and LGC-type multinucleated giant cell formation. Gene networks enriched for myeloid cells were anticorrelated with IL-15 treatment and LGC formation. Functional studies revealed that T cells were required for IL-15‒induced LGC formation, involving a direct contact with myeloid cells through CD40L-CD40 interaction and IFN-γ release. These data indicate that IL-15 induces LGC formation through the direct interaction of activated T cells and myeloid cells.

Published
2020

36. Genome Composition and Divergence of the Novel Coronavirus (2019-nCoV) Originating in China

Author

Wu, Aiping, Peng, Yousong, Huang, Baoying, Ding, Xiao, Wang, Xianyue, Niu, Peihua, Meng, Jing, Zhu, Zhaozhong, Zhang, Zheng, Wang, Jiangyuan, Sheng, Jie, Quan, Lijun, Xia, Zanxian, Tan, Wenjie, Cheng, Genhong, and Jiang, Taijiao

Subjects
Infectious Diseases, Emerging Infectious Diseases, Human Genome, Genetics, Pneumonia, Lung, Pneumonia & Influenza, Good Health and Well Being, Amino Acid Substitution, Betacoronavirus, COVID-19, China, Coronavirus Infections, Genome, Viral, Middle East Respiratory Syndrome Coronavirus, Pandemics, Phylogeny, Pneumonia, Viral, Severe acute respiratory syndrome-related coronavirus, SARS-CoV-2, Microbiology, Medical Microbiology, Immunology
Abstract

An in-depth annotation of the newly discovered coronavirus (2019-nCoV) genome has revealed differences between 2019-nCoV and severe acute respiratory syndrome (SARS) or SARS-like coronaviruses. A systematic comparison identified 380 amino acid substitutions between these coronaviruses, which may have caused functional and pathogenic divergence of 2019-nCoV.

Published
2020

43. Azithromycin Protects against Zika virus Infection by Upregulating virus-induced Type I and III Interferon Responses.

Author

Li, Chunfeng, Zu, Shulong, Deng, Yong-Qiang, Li, Dapei, Parvatiyar, Kislay, Quanquin, Natalie, Shang, Jingzhe, Sun, Nina, Su, Jiaqi, Liu, Zhenyang, Wang, Min, Aliyari, Saba R, Li, Xiao-Feng, Wu, Aiping, Ma, Feng, Shi, Yi, Nielsevn-Saines, Karin, Jung, Jae U, Qin, Frank Xiao-Feng, Qin, Cheng-Feng, and Cheng, Genhong

Subjects
Infectious Diseases, Prevention, Emerging Infectious Diseases, Biodefense, Vaccine Related, HIV/AIDS, 2.2 Factors relating to the physical environment, 2.1 Biological and endogenous factors, Aetiology, Infection, Good Health and Well Being, FDA-approved drug, azithromycin, Zika virus, type I and III interferon responses, antibiotics, antiviral agents, innate immunity, interferons, Microbiology, Medical Microbiology, Pharmacology and Pharmaceutical Sciences
Abstract

Azithromycin (AZM) is a widely used antibiotic, with additional antiviral and anti-inflammatory properties that remain poorly understood. Although Zika virus (ZIKV) poses a significant threat to global health, there are currently no vaccines or effective therapeutics against it. Herein, we report that AZM effectively suppresses ZIKV infection in vitro by targeting a late stage in the viral life cycle. Besides that, AZM upregulates the expression of host type I and III interferons and several of their downstream interferon-stimulated genes (ISGs) in response to ZIKV infection. In particular, we found that AZM upregulates the expression of MDA5 and RIG-I, pathogen recognition receptors (PRRs) induced by ZIKV infection, and increases the levels of phosphorylated TBK1 and IRF3. Interestingly, AZM treatment upregulates phosphorylation of TBK1, without inducing phosphorylation of IRF3 by itself. These findings highlight the potential use of AZM as a broad antiviral agent to combat viral infection and prevent ZIKV associated devastating clinical outcomes, such as congenital microcephaly.

Published
2019

Catalog

Books, media, physical & digital resources
See catalog results